News
-
-
-
COMMUNIQUÉ DE PRESSE
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387 -
-
-
COMMUNIQUÉ DE PRESSE
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
NanoViricides, Inc. declares its business is not affected by US tariff policies or spending cuts, focusing on developing broad-spectrum antiviral drugs. The company's NV-387 shows potential for treating measles -
